Richard S. Levy - Nov 3, 2023 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
Director
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Stock symbol
KNSA
Transactions as of
Nov 3, 2023
Transactions value $
$0
Form type
4
Date filed
11/7/2023, 04:33 PM
Previous filing
Jul 3, 2023
Next filing
Apr 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Options Exercise +2.78K +55.54% 7.78K Nov 3, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Units Award $0 +2.78K $0.00 2.78K Nov 3, 2023 Class A Common Shares 2.78K Direct F1, F2
transaction KNSA Restricted Share Units Options Exercise $0 -2.78K -100% $0.00* 0 Nov 3, 2023 Class A Common Shares 2.78K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2 The RSUs vested immediately upon grant on November 3, 2023; there was no expiration date for the RSUs.